Annual report pursuant to Section 13 and 15(d)

License Revenue (Details)

v3.22.1
License Revenue (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Aug. 31, 2020
Apr. 30, 2018
Dec. 31, 2021
Dec. 31, 2020
Licensing Arrangements        
Total revenue     $ 567 $ 3,069
Pharmbio Korea Inc        
Licensing Arrangements        
Upfront payment   $ 3,000    
Withholding taxes   $ 500    
Time period for written notice to terminate license agreement   180 days    
Pharmbio Korea Inc | Minimum        
Licensing Arrangements        
Time period to form a committee prior to the anticipated date of regulatory approval   6 months    
Pharmbio Korea Inc | Maximum        
Licensing Arrangements        
Commercialization milestone payments   $ 500    
Royalties on product sales, percentage   20.00%    
Jiangsu Nhwa Pharmaceutical Co Ltd | Minimum        
Licensing Arrangements        
Time period to form a committee prior to the anticipated date of regulatory approval   6 months    
Jiangsu Nhwa Pharmaceutical Co Ltd | Licensing agreements for development and commercialization        
Licensing Arrangements        
Upfront payment $ 3,000 $ 2,500    
Withholding taxes $ 300 $ 300    
Time period for written notice to terminate license agreement     180 days  
Milestone payment upon regulatory approval in China     $ 3,000  
Milestone payment upon sales targets reached in China     $ 6,000  
Royalty percentage on net product sales in China after milestones met     10.00%  
License revenue        
Licensing Arrangements        
Total revenue     $ 69 3,000
License revenue | Jiangsu Nhwa Pharmaceutical Co Ltd        
Licensing Arrangements        
Total revenue     $ 100 $ 3,000